Overall Survival Associated With Ixazomib, Lenalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
J. Clin. Oncol 2021 Jun 11;[EPub Ahead of Print], PG Richardson, SK Kumar, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, P Ganly, BW Baker, SR Jackson, AM Stoppa, P Gimsing, L Garderet, C Touzeau, FK Buadi, JP Laubach, M Cavo, M Darif, R Labotka, D Berg, P MoreauFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.